Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1083686

	registered interest
	date	07/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many patients have been prescribed cannabis-based products for medicinal use; and how many were (a) private prescriptions and (b) prescriptions funded by NHS or NHS Scottish.
	tabling member constituency	Kilmarnock and Loudoun
	tabling member printed	Alan Brown
	uin	229804
	answer	answer is ministerial correction date of answer 12/03/2019 answer text <p>NHS England has set up systems to monitor the prescribing of cannabis-based products for medicinal use via the NHS Business Services Authority and NHS England Controlled Drugs Accountable Officers. We expect the first data to be available by the end of March 2019. In Scotland, work is underway to establish similar systems.</p><p> </p><p>There are 95,532 specialist doctors registered on the General Medical Council’s Specialist Register. The law allows any specialist doctor to prescribe cannabis-based products for medicinal use. Specialist doctors may decide to prescribe these products on a case-by-case basis, and where it is clinically appropriate. The Department does not hold information on how many of those practitioners operate private practices and are National Health Service or NHS Scotland employees or where they work.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 229805 question first answered 12/03/2019 16:17:58 answering member 4067 label Biography information for Steve Brine
	tabling member	4470 label Biography information for Alan Brown

1083687

	registered interest
	date	07/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many medical practitioners are registered to prescribe cannabis-based products for medicinal use; how many of those practitioners (a) operate private practices and (b) are NHS or NHS Scotland employees; and if he will list the (i) Trusts and (ii) Health boards at which each of those NHS and NHS Scotland employee works.
	tabling member constituency	Kilmarnock and Loudoun
	tabling member printed	Alan Brown
	uin	229805
	answer	answer is ministerial correction date of answer 12/03/2019 answer text <p>NHS England has set up systems to monitor the prescribing of cannabis-based products for medicinal use via the NHS Business Services Authority and NHS England Controlled Drugs Accountable Officers. We expect the first data to be available by the end of March 2019. In Scotland, work is underway to establish similar systems.</p><p> </p><p>There are 95,532 specialist doctors registered on the General Medical Council’s Specialist Register. The law allows any specialist doctor to prescribe cannabis-based products for medicinal use. Specialist doctors may decide to prescribe these products on a case-by-case basis, and where it is clinically appropriate. The Department does not hold information on how many of those practitioners operate private practices and are National Health Service or NHS Scotland employees or where they work.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 229804 question first answered 12/03/2019 16:17:58 answering member 4067 label Biography information for Steve Brine
	tabling member	4470 label Biography information for Alan Brown

1156146

	registered interest
	date	24/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what progress has been made for the provision of medical cannabis on the NHS.
	tabling member constituency	South Leicestershire
	tabling member printed	Alberto Costa
	uin	5043
	answer	answer is ministerial correction date of answer 01/11/2019 answer text <p>The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s ‘Specialist Register’ to prescribe cannabis-based products for medicinal use, where clinically appropriate and in the best interest of patients. The Government has been clear that decisions on whether to prescribe these products must remain a clinical one.</p><p> </p><p>Following a meeting in Parliament with the families of patients seeking access to medicinal cannabis, my Rt. hon. Friend the Secretary of State for Health and Social Care asked NHS England and NHS Improvement to undertake a rapid process review into any barriers to prescribing on the National Health Service, where clinically appropriate. The review report is now published and the Department is working closely with NHS England and NHS Improvement and other delivery partners to implement the report’s recommendations. This includes promoting more high-quality research through the publicly funded National Institute for Health Research to develop the evidence base and exploring alternative studies to help children and young adults with treatment resistance epilepsy who are currently receiving cannabis-based medicines. We have also contacted all producers of cannabis-based products, known to have an interest in supplying the United Kingdom market, to encourage and support research applications to develop the evidence base further.</p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 01/11/2019 12:17:20 answering member 4380 label Biography information for Jo Churchill
	tabling member	4439 label Biography information for Alberto Costa

1240751

	registered interest
	date	06/10/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve access to medicinal cannabis.
	tabling member constituency	South Leicestershire
	tabling member printed	Alberto Costa
	uin	99651
	answer	answer is ministerial correction date of answer 23/10/2020 answer text <p>We continue to work hard with the health system, industry and researchers to improve the evidence base for other cannabis-based medicines, and to implement the recommendations of NHS England and NHS Improvement’s review on barriers to accessing unlicensed cannabis based medicinal products. This includes the design of clinical trials and the establishment of a new independent specialist clinical network to provide impartial evidence-based advice to clinicians treating patients with refractory epilepsy.</p><p>Two licensed cannabis-based medicines: Sativex – for the treatment of spasticity in multiple sclerosis patients; and Epidyolex – for the treatment of seizures associated with two rare forms of epilepsy, have recently been made available for prescribing on the National Health Service for patients where clinically appropriate. This follows clear demonstrated evidence of their safety, clinical and cost effectiveness. Further evidence is required to support the routine use of unlicensed cannabis-based products in the NHS.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 23/10/2020 08:16:58 answering member 4380 label Biography information for Jo Churchill
	tabling member	4439 label Biography information for Alberto Costa

1420881

	registered interest
	date	08/02/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent progress his Department has made on discussions with the Dutch Government to allow the continued supply of bedrocan oil beyond 1 April 2022.
	tabling member constituency	South Leicestershire
	tabling member printed	Alberto Costa
	uin	120809
	answer	answer is ministerial correction date of answer 14/02/2022 answer text <p>The Dutch Government has confirmed that they will extend the current waiver to allow continued supply of Bedrocan oils against United Kingdom prescriptions for existing patients until 1 April 2022 to allow for domestic production to be established. The Department continues to work closely with the Dutch Government, the Home Office and the Medicines and Healthcare products Regulatory Agency to ensure continuity of supply of Bedrocan oils beyond this period.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 14/02/2022 14:34:43 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4439 label Biography information for Alberto Costa

1439806

	registered interest
	date	10/03/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what progress his Department has made on the manufacture of bedrocan oil in the UK.
	tabling member constituency	South Leicestershire
	tabling member printed	Alberto Costa
	uin	138068
	answer	answer is ministerial correction date of answer 15/03/2022 answer text <p>The current producer of Bedrocan oils in the Netherlands and the chosen United Kingdom commercial partner are progressing the technology transfer agreement to manufacture three Bedrocan oils - Bedica, Bedrolite and Bedrocan - in the UK. The UK manufacturer has been inspected by the Medicines and Healthcare products Regulatory Agency and Home Office to obtain the necessary regulatory approvals and has agreement in principle to produce herbal medicines of this type following the successful production of Bedrolite oils.</p><p>The Dutch Government has agreed to allow continued supply of all three Bedrocan oils against UK prescriptions for existing patients for a further three months until 1 July 2022. This should allow for domestic production to be established and approved for all three oils.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 15/03/2022 14:59:23 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4439 label Biography information for Alberto Costa

1439807

	registered interest
	date	10/03/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the outcomes of observational trials of medical cannabis for children with severe epilepsy.
	tabling member constituency	South Leicestershire
	tabling member printed	Alberto Costa
	uin	138069
	answer	answer is ministerial correction date of answer 15/03/2022 answer text <p>The National Institute for Health and Care Excellence (NICE) reviewed the best available evidence when developing its guideline on prescribing of cannabis-based medicinal products. However, NICE found that current research is limited and of low quality. Observational studies with a small number of patients do not produce results which are sufficiently robust to inform routine clinical or commissioning decisions. To develop evidence on medical cannabis, the Department, via the National Institute for Health Research, will be supporting two randomised controlled trials into epilepsy in adults and children. The trials will commence as soon as possible and results will be published once the trials have completed and the findings have been peer reviewed.</p> answering member constituency Lewes answering member printed Maria Caulfield grouped question UIN 138070 question first answered 15/03/2022 17:43:05 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4439 label Biography information for Alberto Costa

1439808

	registered interest
	date	10/03/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when his Department will publish details of the proposed randomised control trials for medicinal cannabis.
	tabling member constituency	South Leicestershire
	tabling member printed	Alberto Costa
	uin	138070
	answer	answer is ministerial correction date of answer 15/03/2022 answer text <p>The National Institute for Health and Care Excellence (NICE) reviewed the best available evidence when developing its guideline on prescribing of cannabis-based medicinal products. However, NICE found that current research is limited and of low quality. Observational studies with a small number of patients do not produce results which are sufficiently robust to inform routine clinical or commissioning decisions. To develop evidence on medical cannabis, the Department, via the National Institute for Health Research, will be supporting two randomised controlled trials into epilepsy in adults and children. The trials will commence as soon as possible and results will be published once the trials have completed and the findings have been peer reviewed.</p> answering member constituency Lewes answering member printed Maria Caulfield grouped question UIN 138069 question first answered 15/03/2022 17:43:05 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4439 label Biography information for Alberto Costa

1256043

	registered interest
	date	26/11/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with the Food Standards Agency on the steps it is taking to educate consumers on the safety of unauthorised products containing CBD.
	tabling member constituency	Nottingham North
	tabling member printed	Alex Norris
	uin	121342
	answer	answer is ministerial correction date of answer 02/12/2020 answer text <p>CBD products currently on the market is contrary to the requirements of the Novel Foods Regulations. A proportionate approach to enforcement has been taken in the short term but manufacturers must apply to the Food Standards Agency (FSA) by the end of March 2021 to begin the authorisation process. From that time, only products with validated applications in the pipeline will be allowed on the market.</p><p>In the meantime, on the basis of advice from the independent United Kingdom Committee on Toxicity, the FSA has publicly advised that an average adult should not consume more than 70 milligrams per day and vulnerable groups should not consume these products.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 02/12/2020 16:44:14 answering member 4380 label Biography information for Jo Churchill previous answer version 65825 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
	tabling member	4641 label Biography information for Alex Norris

1256852

	registered interest
	date	30/11/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans he has to ensure the hierarchy of medicines is enforced in relation to cannabis-based medicinal products.
	tabling member constituency	Nottingham North
	tabling member printed	Alex Norris
	uin	122859
	answer	answer is ministerial correction date of answer 09/12/2020 answer text <p>NHS England has disseminated resources to support clinicians and guidance on the prescribing process for cannabis-based products for medicinal use (CBPMs).</p><p>The vast majority of CBPMs are unlicensed medicines, which have not been assessed by the medicines regulator. As such these are not first line treatments and specialist doctors must take into consideration the clinical evidence base, and the guidance from the General Medical Council (GMC) on licensed, off label and unlicensed medicines and local National Health Service governance systems when making a decision to prescribe.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 09/12/2020 14:03:10 answering member 4380 label Biography information for Jo Churchill previous answer version 66555 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
	tabling member	4641 label Biography information for Alex Norris